Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$86.53 USD
+0.55 (0.64%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.53 USD
+0.55 (0.64%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Zacks News
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal
by Zacks Equity Research
Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 6.36% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Axsome (AXSM) This Earnings Season?
by Zacks Equity Research
Axsome (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why You Should Consider Investing in JAZZ Stock Now
by Zacks Equity Research
JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
by Zacks Equity Research
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.
Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern
by Zacks Equity Research
Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.
Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why
by Zacks Equity Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.
Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Axsome Therapeutics (AXSM) closed at $45.33 in the latest trading session, marking a +1.59% move from the prior day.
Axsome Therapeutics (AXSM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Axsome Therapeutics (AXSM) closed the most recent trading day at $44.62, moving +1.06% from the previous trading session.
Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study
by Zacks Equity Research
Axsome Therapeutics (AXSM) enrolls the first patient in a late-stage study of AXS-05 for Alzheimer's disease agitation.
Why Is Axsome (AXSM) Up 26.9% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why
by Zacks Equity Research
Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
by Zacks Equity Research
Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.
Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More
by Zacks Equity Research
Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity
by Zacks Equity Research
The FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major depressive disorder in adults. This becomes the first approved product for the company. Shares rise.
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 10.92% and 8.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.
Jazz's (JAZZ) Q2 Earnings Beat, New Drugs Post Robust Sales
by Zacks Equity Research
JAZZ's Q2 earnings and sales beat expectations on strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. The company affirms its 2022 guidance.